Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 6, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Rationale for using belatacept in combination with sirolimus.

H Wéclawiak1, N Kamar, A Ould-Mohamed

  • 1Department of Nephrology, Dialysis and Organ Transplantation, Toulouse University Hospital, Toulouse, France.

Transplantation Proceedings
|November 25, 2010
PubMed
Summary

New kidney transplant strategies explore combining belatacept with sirolimus (mTOR inhibitors) to enhance immunosuppression while mitigating nephrotoxicity and cytomegalovirus (CMV) risks.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of Labscan 200 and FlexMap 3D Luminex for Anti-HLA Antibodies Monitoring.

HLA·2026
Same author

Determinants of virological outcomes in kidney transplant recipients treated with maribavir for refractory cytomegalovirus infection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2025
Same author

Early screening for chronic liver disease: impact of a FIB-4 first integrated care pathway to identify patients with significant fibrosis.

Scientific reports·2024
Same author

Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7 1506-1514, 2007.

Clinical journal of the American Society of Nephrology : CJASN·2023
Same author

Specificities of Meningitis and Meningo-Encephalitis After Kidney Transplantation: A French Retrospective Cohort Study.

Transplant international : official journal of the European Society for Organ Transplantation·2023
Same author

[Living-donor robotic-assisted kidney transplantation: French academic center experience].

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie·2021

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation Medicine

Background:

  • Kidney transplantation requires long-term immunosuppression, often using nephrotoxic calcineurin inhibitors.
  • Immunological tolerance remains elusive, necessitating alternative or adjunctive immunosuppressive therapies.
  • Mammalian target of rapamycin (mTOR) inhibitors like sirolimus offer immunosuppression with reduced renal toxicity and potential benefits against cytomegalovirus (CMV).

Purpose of the Study:

  • To investigate the rationale for combining belatacept with sirolimus in kidney transplant recipients.
  • To explore a novel immunosuppressive regimen balancing efficacy, renal safety, and infection risk management.

Main Methods:

  • Review of existing data on belatacept and sirolimus efficacy and safety profiles.

Related Experiment Videos

Last Updated: Jun 6, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

  • Analysis of phase III trial outcomes for belatacept in kidney transplantation.
  • Assessment of the potential synergistic or additive effects of combining belatacept and sirolimus.

    • Main Results:

    • Belatacept demonstrates effective immunosuppression and improved cardiovascular outcomes compared to cyclosporine.
    • Sirolimus provides immunosuppression with minimal renal toxicity and beneficial effects on CMV infection.
    • Combining belatacept with sirolimus may offer a superior immunosuppressive strategy, potentially mitigating belatacept-associated infection risks.

    Conclusions:

    • Combining belatacept and sirolimus presents a promising approach for kidney transplant immunosuppression.
    • This combination may improve long-term graft survival and patient outcomes by addressing nephrotoxicity and infection concerns.
    • Further clinical investigation is warranted to validate the safety and efficacy of this combined regimen.